Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-09-2023 | Head and Neck

A novel and independent survival prognostic model for OSCC: the functions and prognostic values of RNA-binding proteins

Authors: Shanshan Wang, Shuang Liu, Yaomin Zhu, Baorong Zhang, Yongtao Yang, Limei Li, Yingying Sun, Long Zhang, Lina Fan, Xuegang Hu, Chunyu Huang

Published in: European Archives of Oto-Rhino-Laryngology | Issue 1/2024

Abstract

Background

Oral squamous cell carcinoma (OSCC), exhibiting high morbidity and malignancy, is the most common type of oral cancer. The abnormal expression of RNA-binding proteins (RBPs) plays important roles in the occurrence and progression of cancer. The objective of the present study was to establish a prognostic assessment model of RBPs and to evaluate the prognosis of OSCC patients.

Methods

Gene expression data in The Cancer Genome Atlas (TCGA) were analyzed by univariate Cox regression analysis model that established a novel nine RBPs, which were used to build a prognostic risk model. A multivariate Cox proportional regression model and the survival analysis were used to evaluate the prognostic risk model. Moreover, the receive operator curve (ROC) analysis was tested further the efficiency of prognostic risk model based on data from TCGA database and Gene Expression Omnibus (GEO).

Results

Nine RBPs’ signatures (ACO1, G3BP1, NMD3, RNGTT, ZNF385A, SARS, CARS2, YARS and SMAD6) with prognostic value were identified in OSCC patients. Subsequently, the patients were further categorized into high-risk group and low-risk in the overall survival (OS) and disease-free survival (DFS), and external validation dataset. ROC analysis was significant for both the TCGA and GEO. Moreover, GSEA revealed that patients in the high-risk group significantly enriched in many critical pathways correlated with tumorigenesis than the low, including cell cycle, adheres junctions, oocyte meiosis, spliceosome, ERBB signaling pathway and ubiquitin-mediated proteolysis.

Conclusions

Collectively, we developed and validated a novel robust nine RBPs for OSCC prognosis prediction. The nine RBPs could serve as an independent and reliable prognostic biomarker and guiding clinical therapy for OSCC patients.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A, Global cancer statistics (2018) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(2018):394–424PubMed

Zhao X, Sun S, Zeng X, Cui L (2018) Expression profiles analysis identifies a novel three-mRNA signature to predict overall survival in oral squamous cell carcinoma. Am J Cancer Res 8:450–461PubMedPubMedCentral

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-386PubMed

Corley M, Burns MC, Yeo GW (2020) How RNA-binding proteins interact with RNA: molecules and mechanisms. Mol Cell 78:9–29PubMedPubMedCentral

Hentze MW, Castello A, Schwarzl T, Preiss T (2018) A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol 19:327–341PubMed

Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X, Zheng L (2020) RNA-binding proteins in tumor progression. J Hematol Oncol 13:90PubMedPubMedCentral

Chatterji P, Rustgi AK (2018) RNA binding proteins in intestinal epithelial biology and colorectal cancer. Trends Mol Med 24:490–506PubMedPubMedCentral

Xie M, Ma T, Xue J, Ma H, Sun M, Zhang Z, Liu M, Liu Y, Ju S, Wang Z, De W (2019) The long intergenic non-protein coding RNA 707 promotes proliferation and metastasis of gastric cancer by interacting with mRNA stabilizing protein HuR. Cancer Lett 443:67–79PubMed

McCullough MJ, Prasad G, Farah CS (2010) Oral mucosal malignancy and potentially malignant lesions: an update on the epidemiology, risk factors, diagnosis and management. Aust Dent J 55(Suppl 1):61–65PubMed

10.

Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA (2018) Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer. Genome Med 10:54PubMedPubMedCentral

11.

Pereira B, Billaud M, Almeida R (2017) RNA-binding proteins in cancer: old players and new actors, trends. Cancer 3:506–528

12.

Coppin L, Leclerc J, Vincent A, Porchet N, Pigny P (2018) Messenger RNA life-cycle in cancer cells: emerging role of conventional and non-conventional RNA-binding proteins. Int J Mol Sci 19:650PubMedPubMedCentral

13.

Mucha B, Qie S, Bajpai S, Tarallo V, Diehl JN, Tedeschi F, Zhou G, Gao Z, Flashner S, Klein-Szanto AJ, Hibshoosh H, Masataka S, Chajewski OS, Majsterek I, Pytel D, Hatzoglou M, Der CJ, Nakagawa H, Bass AJ, Wong KK, Fuchs SY, Rustgi AK, Jankowsky E, Diehl JA (2022) Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translation. Nat Commun 13:6614PubMedPubMedCentral

14.

Lu X, Zhong J, Liu L, Zhang W, Zhao S, Chen L, Wei Y, Zhang H, Wu J, Chen W, Ge F (2022) The function and regulatory mechanism of RNA-binding proteins in breast cancer and their future clinical treatment prospects. Front Oncol 12:929037PubMedPubMedCentral

15.

Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348PubMed

16.

Syrigos KN, Katirtzoglou N, Kotteas E, Harrington K (2008) Adhesion molecules in lung cancer: implications in the pathogenesis and management. Curr Pharm Des 14:2173–2183PubMed

17.

Schimmel P, Tao J, Hill J (1998) Aminoacyl tRNA synthetases as targets for new anti-infectives. FASEB J 12:1599–1609PubMed

18.

Nowaczyk MJ, Huang L, Tarnopolsky M, Schwartzentruber J, Majewski J, Bulman DE, Hartley T, Boycott KM (2017) A novel multisystem disease associated with recessive mutations in the tyrosyl-tRNA synthetase (YARS) gene. Am J Med Genet A 173:126–134PubMed

19.

Tracewska-Siemiątkowska A, Haer-Wigman L, Bosch D, Nickerson D, Bamshad MJ, van de Vorst M, Rendtorff ND, Möller C, Kjellström U, Andréasson S, Cremers F, Tranebjærg L (2017) An expanded multi-organ disease phenotype associated with mutations in YARS. Genes (Basel). https://doi.org/10.3390/genes8120381CrossRefPubMed

20.

Fuchs SA, Schene IF, Kok G, Jansen JM, Nikkels P, van Gassen K, Terheggen-Lagro S, van der Crabben SN, Hoeks SE, Niers L, Wolf NI, de Vries MC, Koolen DA, Houwen R, Mulder MF, van Hasselt PM (2019) Aminoacyl-tRNA synthetase deficiencies in search of common themes. Genet Med 21:319–330PubMed

21.

Zhang C, Lin X, Zhao Q, Wang Y, Jiang F, Ji C, Li Y, Gao J, Li J, Shen L (2020) YARS as an oncogenic protein that promotes gastric cancer progression through activating PI3K-Akt signaling. J Cancer Res Clin Oncol 146:329–342PubMedPubMedCentral

22.

Hsu CW, Chang KP, Huang Y, Liu HP, Hsueh PC, Gu PW, Yen WC, Wu CC (2019) Proteomic profiling of paired interstitial fluids reveals dysregulated pathways and salivary NID1 as a biomarker of oral cavity squamous cell carcinoma. Mol Cell Proteomics 18:1939–1949PubMedPubMedCentral

23.

Fukui H, Hanaoka R, Kawahara A (2009) Noncanonical activity of seryl-tRNA synthetase is involved in vascular development. Circ Res 104:1253–1259PubMed

24.

Herzog W, Müller K, Huisken J, Stainier DY (2009) Genetic evidence for a noncanonical function of seryl-tRNA synthetase in vascular development. Circ Res 104:1260–1266PubMedPubMedCentral

25.

Shi Y, Xu X, Zhang Q, Fu G, Mo Z, Wang GS, Kishi S, Yang XL (2014) tRNA synthetase counteracts c-Myc to develop functional vasculature. Elife 3:e02349PubMedPubMedCentral

26.

Zou G, Zhang X, Wang L, Li X, Xie T, Zhao J, Yan J, Wang L, Ye H, Jiao S, Xiang R, Shi Y (2020) Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics 10:6839–6853PubMedPubMedCentral

27.

Panse VG, Johnson AW (2010) Maturation of eukaryotic ribosomes: acquisition of functionality. Trends Biochem Sci 35:260–266PubMedPubMedCentral

28.

Sengupta J, Bussiere C, Pallesen J, West M, Johnson AW, Frank J (2010) Characterization of the nuclear export adaptor protein Nmd3 in association with the 60S ribosomal subunit. J Cell Biol 189:1079–1086PubMedPubMedCentral

29.

Bai B, Moore HM, Laiho M (2013) CRM1 and its ribosome export adaptor NMD3 localize to the nucleolus and affect rRNA synthesis. Nucleus 4:315–325PubMedPubMedCentral

30.

Chen C, Wang B (2018) Brucea javanica oil emulsion alleviates cachexia induced by Lewis lung cancer cells in mice. J Drug Target 26:222–230PubMed

31.

Ge Y, Jin J, Li J, Ye M, Jin X (2022) The roles of G3BP1 in human diseases (review). Gene 821:146294PubMed

32.

Zhang LN, Zhao L, Yan XL, Huang YH (2019) Loss of G3BP1 suppresses proliferation, migration, and invasion of esophageal cancer cells via Wnt/β-catenin and PI3K/AKT signaling pathways. J Cell Physiol 234:20469–20484PubMed

33.

Hu X, Xia K, Xiong H, Su T (2021) G3BP1 may serve as a potential biomarker of proliferation, apoptosis, and prognosis in oral squamous cell carcinoma. J Oral Pathol Med 50:995–1004PubMed

34.

Hata A, Lagna G, Massagué J, Hemmati-Brivanlou A (1998) Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12:186–197PubMedPubMedCentral

35.

Verschueren K, Huylebroeck D (1999) Remarkable versatility of Smad proteins in the nucleus of transforming growth factor-beta activated cells. Cytokine Growth Factor Rev 10:187–199PubMed

36.

Miyazono K (2000) TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev 11:15–22PubMed

37.

Park JE, Park JS, Jang SY, Park SH, Kim JW, Ki CS, Kim DK (2019) A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm. Mol Genet Genomic Med 7:e620PubMedPubMedCentral

38.

Jeon HS, Dracheva T, Yang SH, Meerzaman D, Fukuoka J, Shakoori A, Shilo K, Travis WD, Jen J (2008) SMAD6 contributes to patient survival in non-small cell lung cancer and its knockdown reestablishes TGF-beta homeostasis in lung cancer cells. Cancer Res 68:9686–9692PubMedPubMedCentral

39.

Choi KC, Lee YS, Lim S, Choi HK, Lee CH, Lee EK, Hong S, Kim IH, Kim SJ, Park SH (2006) Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor signaling through direct interaction with the adaptor Pellino-1. Nat Immunol 7:1057–1065PubMed

40.

Lönn P, Morén A, Raja E, Dahl M, Moustakas A (2009) Regulating the stability of TGFbeta receptors and Smads. Cell Res 19:21–35PubMed

41.

Tan HL, Glen E, Töpf A, Hall D, O’Sullivan JJ, Sneddon L, Wren C, Avery P, Lewis RJ, ten Dijke P, Arthur HM, Goodship JA, Keavney BD (2012) Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation. Hum Mutat 33:720–727PubMedPubMedCentral

42.

Lu W, Sun J, Zhou H, Wang F, Zhao C, Li K, Fan C, Ding G, Wang J (2020) HNF1B inhibits cell proliferation via repression of SMAD6 expression in prostate cancer. J Cell Mol Med 24:14539–14548PubMedPubMedCentral

43.

Bayat Z, Ghaemi Z, Behmanesh M, Soltani BM (2021) Hsa-miR-186-5p regulates TGFβ signaling pathway through expression suppression of SMAD6 and SMAD7 genes in colorectal cancer. Biol Chem 402:469–480PubMed

44.

Liu L, Zhang C, Wang J, Liu X, Qu H, Zhang G, Liang T, Wang J, Zhang J (2021) A high level of lncFGD5-AS1 inhibits epithelial-to-Mesenchymal transition by regulating the miR-196a-5p/SMAD6/BMP axis in gastric Cancer. BMC Cancer 21:453PubMedPubMedCentral

45.

Park JH, Ameri AH, Dempsey KE, Conrad DN, Kem M, Mino-Kenudson M, Demehri S (2021) Nuclear IL-33/SMAD signaling axis promotes cancer development in chronic inflammation. EMBO J 40:e106151PubMedPubMedCentral

46.

Mi W, Zheng Z, Lu JD, Duan SQ, Zhang J, Zhang HQ, Ding YX, Yin J, Cao F, Zhang J, Li F (2022) KLF16 promotes pancreatic adenocarcinoma cell proliferation and migration by positively regulating SMAD6. World J Gastrointest Oncol 14:2157–2169PubMedPubMedCentral

47.

Miyazono K (2000) Positive and negative regulation of TGF-beta signaling. J Cell Sci 113(Pt 7):1101–1109PubMed

48.

Osawa H, Nakajima M, Kato H, Fukuchi M, Kuwano H (2004) Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. Anticancer Res 24:3703–3709PubMed

49.

Mangone FR, Walder F, Maistro S, Pasini FS, Lehn CN, Carvalho MB, Brentani MM, Snitcovsky I, Federico MH (2010) Smad2 and Smad6 as predictors of overall survival in oral squamous cell carcinoma patients. Mol Cancer 9:106PubMedPubMedCentral

Title: A novel and independent survival prognostic model for OSCC: the functions and prognostic values of RNA-binding proteins
Authors: Shanshan Wang
Shuang Liu
Yaomin Zhu
Baorong Zhang
Yongtao Yang
Limei Li
Yingying Sun
Long Zhang
Lina Fan
Xuegang Hu
Chunyu Huang
Publication date: 01-09-2023
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Oto-Rhino-Laryngology / Issue 1/2024
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-023-08200-9

2024 ASCO Annual Meeting

Springer Medicine

A novel and independent survival prognostic model for OSCC: the functions and prognostic values of RNA-binding proteins

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Exploring the anti-inflammatory potential of topical hyaluronic acid for vocal fold injury in a rat model

Auditory outcomes after scala vestibuli array insertion are similar to those after scala tympani insertion 1 year after cochlear implantation

The influence of intraoperative auditory brainstem responses on vibroplasty coupling-quality and analysis of the impact of different fixation steps on the coupling

Efficacy of platelet-rich plasma (PRP) in benign vocal fold lesions: a systematic review and meta-analysis

Differences in residual volume above different tracheostomy tube cuffs depending on tube structure, tube tilt angle, and liquid viscosity

Invasive Eumycotic mycetoma of the nasal septum in a post-dialysis patient: A case report